Glaukos announces commercial availability of Epioxa for the treatment of keratoconus

Glaukos Corporation has announced the commercial availability of Epioxa HD / Epioxa for the treatment of keratoconus, a rare corneal disease. The product is now available for ordering directly from the company and through its specialty pharmaceutical distribution network, according to a news release.¹

“We are delighted to announce that Epioxa is now commercially available, ushering in a new standard of care for patients suffering from keratoconus with the first FDA-approved topical drug therapy that does not require removal of the corneal epithelium,” said Thomas Burns, Glaukos chairman and chief executive officer, in the release. “Epioxa is designed to improve patient comfort and minimize recovery time, representing a game-changing new interventional keratoconus treatment for patients. Our teams have been diligently preparing for this launch, and we are excited to bring this innovative therapy to market for patients.”

According to the company, Epioxa is an advancement in corneal cross-linking designed as an incision-free alternative to traditional procedures. The topical therapy, which is catalyzed by enriched oxygen and light, is intended to reduce pain associated with epithelium removal, streamline the procedure, and minimize recovery while delivering clinical outcomes.¹

Glaukos said it plans to increase investments in patient awareness, education, and access as part of the launch. Initiatives include patient access support programs, a patient access liaison team, a co-pay assistance program, a patient assistance program for uninsured individuals, and awareness and detection campaigns aimed at earlier screening and diagnosis.¹

On Epioxa

Epioxa HD (riboflavin 5’-phosphate ophthalmic solution) 0.239% and Epioxa (riboflavin 5’-phosphate ophthalmic solution) 0.177% are indicated for use in epithelium-on corneal collagen cross-linking for the treatment of keratoconus in adults and pediatric patients aged 13 years and older, in conjunction with the O2n System and the Boost Goggles.¹

Approved by the FDA in October 2025, Epioxa was supported by data from 2 prospective, randomized, multicenter, double-masked phase 3 pivotal trials involving more than 400 patients. The trials both reached their primary effectiveness targets and exhibited positive safety and tolerability outcomes.²

Reference:

1. Glaukos announces commercial availability of Epioxa^™, a transformative innovation in interventional keratoconus care. News release. Businesswire. March 19, 2026. Accessed March 19, 2026. https://www.businesswire.com/news/home/20260319138395/en/Glaukos-Announces-Commercial-Availability-of-Epioxa-a-Transformative-Innovation-in-Interventional-Keratoconus-Care

2. Stevenson S. Glaukos’ Epioxa gains FDA nod for noninvasive keratoconus therapy. Optometry Times. October 20, 2025. Accessed March 19, 2026. https://www.optometrytimes.com/view/glaukos-epioxa-gains-fda-nod-for-non-invasive-keratoconus-therapy